daratumumab
Janssen
['mmsm']
ifm study of dara-krd induction and tandem asct in hrmm. 50% had +1q, 68% double hit. 28% discontinued. 18-month pfs 92%, os 96%. #mmsm #asco22 
Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????